New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Clinical trial NCT07110662 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07110662
Sponsor: Hospices Civils de Lyon
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Toxic Epidermal Necrolysis Immunotherapy Cutaneous Adverse Drug Reactions (CADR)

Start date: 2025-10-29
Primary completion: 2028-10-29
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.